{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-041462","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.353018+00:00","generated_at":"2026-06-04T04:49:56.335695+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Judge lifts YUTREPIA injunction; Tyvaso PH-ILD exclusivity expires March 31","bullets":["March 28: Judge Andrews set aside August 2022 injunction; FDA can now approve YUTREPIA NDA.","March 29: Judge Bates denied United Therapeutics' motion for TRO/preliminary injunction against FDA approval.","March 31: Regulatory exclusivity for Tyvaso in PH-ILD expired; FDA can act on YUTREPIA amended NDA.","United Therapeutics filed appeal and new lawsuits, but none currently block YUTREPIA launch.","Liquidia commercial team ready to launch for PAH and PH-ILD upon FDA final approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-041462","json":"https://secwatch.observer/filing/0001104659-24-041462.json","markdown":"https://secwatch.observer/filing/0001104659-24-041462.md","text":"https://secwatch.observer/filing/0001104659-24-041462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924041462/0001104659-24-041462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924041462/tm2410292d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:49:56.335695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}